Get started
Author

Oluwakemi D. Alonge

Observed names: Kemi Alonge, Oluwakemi Alonge, Oluwakemi D Alonge, Oluwakemi D. Alonge
ORCID: 0000-0002-0363-6229
Observed ORCID: 0000-0002-0363-6229
OpenAlex ID: A5025633600
Application of the theoretical domains framework to identify factors influencing catch-up HPV vaccinations among male college students in the United States: A review of evidence and recommendations
2023 · Olufunto A. Olusanya, Aditi Tomar, et al. · Vaccine · 17
Long-term Neutralizing Antibody Levels Against Measles and Rubella Viruses Among Adults With 3 Doses of Measles-Mumps-Rubella Vaccine
2024 · Oluwakemi D Alonge, Mona Marin, et al. · Open Forum Infectious Diseases · 13
PDF
Pharmacovigilance Rapid Alert System for Consumer Reporting (PRASCOR): A Look at Its Quantitative Contribution to Spontaneous Reporting in Nigeria from August 2012 to February 2017
2018 · Comfort Kunak Ogar, Ali Ibrahim, et al. · Pharmaceutical Medicine · 9
Young adult perspectives on deciding to get human papillomavirus (HPV) vaccination in urban and rural communities: A qualitative research study
2025 · Maria E. Sundaram, Ben Christianson, et al. · Human Vaccines & Immunotherapeutics · 4
PDF
Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al. · Cancer Epidemiology Biomarkers & Prevention · 3
Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024
2025 · Huong Q Nguyen, Oluwakemi D Alonge, et al. · Journal of the Pediatric Infectious Diseases Society · 3
PDF
Seasonal Incidence of Human Metapneumovirus in High‐Risk Adults With Medically Attended Acute Respiratory Illness in a Rural US Community
2025 · Maria E. Sundaram, David L. McClure, et al. · Influenza and Other Respiratory Viruses · 3
PDF
Seasonal Incidence of Medically Attended Respiratory Syncytial Virus Infection From 2015 to 2019 in a Cohort of Adults With High-risk Conditions
2025 · Maria E Sundaram, David L McClure, et al. · Open Forum Infectious Diseases · 3
COVID-19 Booster Dose Reminder/Recall for Adolescents: Findings From a Health-Care System in Wisconsin
2023 · Oluwakemi D. Alonge, Kayla E. Hanson, et al. · Journal of Adolescent Health · 3
PDF
BMI and Initiation of Cancer Screening: A Closer Look at Differences by Race, Ethnicity, and Sex in a Multicenter Population
2026 · Caryn E. Oshiro, Kara L. Cushing-Haugen, et al. · American Journal of Preventive Medicine · 2
P-670. Absenteeism due to Viral Acute Respiratory Infections in Children, 2024-2025
2026 · Huong Q Nguyen, Jennifer P King, et al. · Open Forum Infectious Diseases · 1
1148. Long-term Persistence of Measles and Rubella Virus Neutralizing Antibody Levels among Adults with Three Doses of Measles-Mumps-Rubella Vaccine
2023 · Oluwakemi Alonge, Mona Marin, et al. · Open Forum Infectious Diseases · 1
Coinfections With Respiratory Syncytial Virus in a Cohort of Adults With High‐Risk Conditions, 2015–2020: A Retrospective Observational Study
2026 · Oluwakemi D. Alonge, Maria E. Sundaram, et al. · Health Science Reports
PDF
Supplementary Figure S6 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Figure S3 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Table S4 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Figure S1 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Figure S5 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Figure S4 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Figure S2 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Table S5 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Data from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Table S3 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Table S1 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Supplementary Table S2 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
2026 · Natalie J. Del Vecchio, V. Paul Doria-Rose, et al.
Works count: 32
Citation count: 61
H-index: 4
I10-index: 2
Year
Topic
Type